Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT05338073 Recruiting - Cancer Clinical Trials

KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

Start date: January 12, 2021
Phase:
Study type: Observational

This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.

NCT ID: NCT05336916 Recruiting - Cancer Clinical Trials

Effectiveness of Blended and Unguided Delivery of Mindfulness-based Cognitive Therapy for Cancer Patients

BUDDY
Start date: January 20, 2021
Phase: N/A
Study type: Interventional

Rationale: Approximately one in three cancer patients and survivors experience significant psychological distress. Previous research has shown that mindfulness-based interventions such as mindfulness-based cognitive therapy (MBCT) can help reduce distress among cancer patients. However, MBCT typically takes place in face-to-face group sessions, which are not easily accessible to many cancer patients. Blended therapist-assisted (combination of group sessions and individual online sessions) and unguided online MBCT interventions may address this problem, however, research on effectiveness of these interventions is missing. Objective: This three-armed, randomized controlled trial (RCT) evaluates the effectiveness and cost-effectiveness of blended therapist-assisted (blended MBCT) and unguided individual internet-based MBCT (online MBCT) compared to treatment-as-usual (TAU) for cancer patients. Secondly, consolidation of treatment effects is studied up to nine months post-treatment. Thirdly, possible working mechanisms and effect moderators are studied. Study design: The current study is a RCT with three arms (blended MBCT, online MBCT and TAU) with assessments at baseline (T0), mid-treatment, post-treatment (T1) and 3 months follow-up (T2). At 3 months follow-up (T2), patients in the TAU arm will be crossed over to blended MBCT or online MBCT (random allocation). Uncontrolled follow-up assessments will be conducted at 6 (T3) and 9 months (T4) follow-up. Study population: 254 adults (>18 years) who have or have had a cancer diagnosis (any stage/any type) will be randomized. Intervention: Patients will be randomly assigned with a 1:1:1 ratio to one of three groups: (1) blended MBCT: patients will be invited to a blended therapist-assisted MBCT program, consisting of 8 weekly sessions (4 online group meetings, 4 online sessions with therapist assistance, and an online silent day), in addition to TAU; (2) online MBCT: patients will be invited to an individual internet-based MBCT program without assistance from a therapist, that consists of 8 weekly sessions and a silent day, in addition to TAU; (3) TAU: patients receive usual care, which can be medical, psychological or paramedical care, except mindfulness interventions. Main study parameters/endpoints: Primary outcome is the difference in Hospital Anxiety and Depression Scale (HADS) total scores between patients in the blended MCBT and TAU arms and between the online MCBT and TAU arms post-treatment (T1).

NCT ID: NCT05336318 Recruiting - Cancer Clinical Trials

Peer2Me: A Peer Supported Program for Adolescent and Young Adult Cancer Patients

Peer2Me
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The present bicentric study has the aim to investigate the effectiveness of the peer supported mentoring program 'Peer2Me' with regard to psychosocial parameters using a prospective Comprehensive Cohort Design. Over a period of three months, acutely ill patients in the intervention group are accompanied by a mentor with the same disease and of similar age. Patients in the control group receive a one-time consultation. Before and after the intervention, mentors and mentees are interviewed about their psychosocial distress and quality of life.

NCT ID: NCT05335928 Recruiting - Cancer Clinical Trials

Abatacept in Immune Checkpoint Inhibitor Myocarditis

ATRIUM
Start date: June 22, 2022
Phase: Phase 3
Study type: Interventional

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

NCT ID: NCT05333016 Recruiting - Cancer Clinical Trials

A Dyadic Approach to Cancer Care: A Feasibility and Efficacy Partner-based Exercise Study

C4C
Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The primary goal of this study will be to assess the feasibility and acceptability of a partner-based 12-week exercise intervention for cancer caregivers and their care recipient. The researchers will also explore the preliminary effectiveness of the exercise program on caregiver burden and physical and psychological health of both the family caregiver and the care recipient.

NCT ID: NCT05331625 Recruiting - Cancer Clinical Trials

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

NCT ID: NCT05327543 Recruiting - Cancer Clinical Trials

Effects of Yoga on the Quality of Life of Breast Cancer Patients

Start date: May 9, 2022
Phase: N/A
Study type: Interventional

This Study investigates the effects of two different yoga interventions on the health-related quality of life in breast cancer patients. Qualitative and quantitative data will be collected.

NCT ID: NCT05324553 Recruiting - Cancer Clinical Trials

Patient Derived Preclinical Models

Start date: April 6, 2022
Phase:
Study type: Observational

Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models. This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.

NCT ID: NCT05320588 Recruiting - Cancer Clinical Trials

A Study in Patients With Advanced Cancers

Start date: March 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

NCT ID: NCT05318196 Recruiting - Cancer Clinical Trials

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

NEPHROGENE2
Start date: September 5, 2022
Phase:
Study type: Observational

Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.